Pomegranate Blood Flow Randomized Trial: What the Evidence Says

Quick Answer

Pomegranate Blood Flow Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026); evidence level 2]
• Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026); evidence level 2]
• These ROS overpower the body's natural antioxidant defenses, causing oxidative stress and damage to proteins, lipids, and DNA. Cell swelling and death result from the breakdown of membrane integrity caused by lipid peroxidation in cellular membranes. [Altimimi Murooj Luai Majeed (2026); evidence level 4]
• Consequently, OSI (OSI = TOS/TAS × 100) was markedly increased in IR (43.26 ± 12.99) and reduced with PSO (IR + PSO high - 8.12 ± 2.64) as shown in. [Altimimi Murooj Luai Majeed (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For pomegranate blood flow randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Haarhuis JE (2026). Effect of a polyphenol-rich pomegranate extract on plasma trimethylamine N-oxide levels following an oral carnitine challenge: a randomized controlled crossover trial in healthy adults.. DOI: 10.3389/fnut.2026.1822840. PMCID: PMC13260717. PMID: 42293209. https://pmc.ncbi.nlm.nih.gov/articles/PMC13260717/
• Altimimi Murooj Luai Majeed (2026). Effects of pomegranate seed oil on lower-extremity ischemia–reperfusion damage: Insights into oxidative stress, inflammation, and cell death. DOI: 10.4103/JAPTR.JAPTR20425. PMCID: PMC13262916. PMID: 42293265. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13262916/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.